Astellas Announces Acceptance of XOSPATA® (gilteritinib) for Regulatory Review in China by the National Medical Products Administration
- Friday, April 10, 2020, 7:03
- Finance
- Add a comment
TOKYO, April 9, 2020 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today a new drug application (NDA) for the oral once-daily therapy XOSPATA® (gilteritinib), for the treatment of adult patients who have relapsed (disease…
About the Author
adminasapcorp has written 41558 stories on this site.